Shionogi Europe

Today, September 13, marks World Sepsis Day. In Europe alone, more than one person dies from sepsis every minute. Of the 2.8 million survivors, 75% are left with long term health effects.¹ Antibiotics are crucial for preventing and treating sepsis, yet their effectiveness is threatened by antimicrobial resistance (AMR). Recently, Dr Ron Daniels, joint CEO of the UK Sepsis Trust, discussed with Shionogi the role of the medical community in driving policy change around AMR – click here to read more about the discussion: https://lnkd.in/eZmv4aBE We urge experts in the clinical community to use their influence at this critical moment in the fight against AMR and sepsis. #WorldSepsisDay #AMR Ref 1: European Sepsis Report — European Sepsis Alliance: https://lnkd.in/eWhBvh_k

Finding sustainable solutions to address the urgent issue of antimicrobial resistance (AMR) will be top of mind for global leaders as they assemble later this month for the High-Level Meeting on AMR, to be held during the United Nations General Assembly (UNGA), and at the G7 Health Ministers' Meeting in Italy in October. As leaders prepare to discuss concrete targets and political commitments against AMR, our President and global CEO, Dr Isao Teshirogi, spoke to Euractiv about why developing new antibiotics is essential, but many large companies have found it difficult to overcome the economic barriers to antimicrobial R&D. Dr Teshirogi explained why pull incentives are needed to maintain sustainable antimicrobial pipelines and remove barriers to progress. AMR is a global challenge that cannot be tackled in isolation. At Shionogi, we are committed to playing our part to help advance the science so that world leaders and clinicians can deliver the best defence against this urgent health crisis. Read the article in full here: https://lnkd.in/eYdYqV4m #AMR #UNHLM #CollectiveAction #G7

In the latest edition of Collaboration Connections, we present Juergen Heitmann, Senior Director for Business Development and Alliance Management at Shionogi Europe. At Shionogi, we embrace our partnerships and build strong relationships across our functions. Juergen discusses the importance of alliance management and how our efforts extend beyond infectious diseases to address the health needs of the ageing population. Check out the link below for further information and to connect with Juergen and the Business Development team. Watch now: https://lnkd.in/e9AifEkN #CollaborationConnections #BusinessGrowth #InfectiousDiseases #HealthcareInnovation #AgeingPopulation #Partnerships #ShionogiEurope

🌍 Shionogi è orgogliosa di aver rappresentato il settore Life Science in occasione dell'evento organizzato dal MIMIT a Tokyo "Invest in Italy: dove innovare è tradizione" 🌱   🚢 Lo scorso 28 Agosto la Nave #AmerigoVespucci, orgoglio della #MarinaMilitareItaliana, è approdata a Tokyo per dare vita presso Villaggio Italia, all’evento organizzato dal Ministero del Made in Italy-#MIMIT dal titolo "Invest in Italy: dove innovare è tradizione”. L'evento ha rappresentato un’occasione unica di incontro tra la delegazione del MIMIT costituita dal Vice Ministro Valentini, l'Ambasciatore italiano Gianluigi Benedetti ed una lista selezionata di Aziende Giapponesi impegnate in diversi settori industriali, tutti orientati all’#innovazione, #sostenibilità e #digitalizzazione e tutte già presenti in Italia con importanti investimenti manifatturieri, tra cui #Shionogi, unica azienda a rappresentare il settore farmaceutico, e per la quale è intervenuta Takuko Sawada Director and Vice Chairman of the Board Shionogi 💡 Shionogi, unica azienda tra quelle presenti a rappresentare il settore delle Life Science, è onorata di aver preso parte a questa discussione cruciale e di contribuire al dialogo sull'importanza della collaborazione internazionale per l'innovazione e la crescita, confermando la propria volontà ad aumentare gli investimenti e l’impegno industriale in Italia nell’ambito della produzione di nuovi ed innovativi antibiotici .   https://lnkd.in/dekJrqWc #Shionogi #InvestInItaly #Innovazione #CrescitaGlobale #CollaborazioneInternazionale #Sostenibilità #Farmaceutica #Italia #Giappone

This week, some of our colleagues from around the world will be attending the World Antimicrobial Resistance (AMR) Congress in Philadelphia – one of the biggest events in the calendar for those involved in fighting AMR.   Here at Shionogi we are determined to continue playing our part in finding innovative solutions to the threat posed by AMR and we are proud to be a sponsor of the 2024 Congress.   #AMRCongress #AMR #WorldAMRCongress

Antimicrobial resistance (AMR) is not just a future concern but an urgent issue requiring action now. Rates of AMR are rising, and each day nearly 100 people die of resistant infections in Europe¹. AMR can affect anyone at anytime, emphasising the need to put patients first. At Shionogi Europe, we recognise that open collaboration is crucial and we are pleased to be working with Health First Europe and the European Patient Forum as part of our patient advocacy efforts. They are looking for patients from across Europe to share their experiences of AMR to raise awareness of the issue. This initiative is a powerful testament to the widespread and diverse nature of the AMR threat. If you have been a patient affected by AMR and wish to share your story, please follow the link: https://lnkd.in/g44swUs8 Ref: 1. European Centre for Disease Prevention and Control: https://lnkd.in/dikwyUrN

At Shionogi, we’re committed to addressing unmet clinical needs and ensuring that evaluation of clinical trials including in invasive fungal diseases is as robust and effective as possible. In 2023, we organised a debate at The 11th Trends in Medical Mycology Congress in Athens, bringing together experts in Invasive Fungal Disease to discuss current definitions of response and outcomes in trials. We are pleased to share that the manuscript from this insightful debate has now been published. This work represents a significant step forward in enhancing the process for evaluating new medications, ultimately supporting efforts to address the unmet needs of patients requiring treatment options for life-threatening infections. Read the full article, "Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate," in this month’s Journal of Antimicrobial Chemotherapy: https://lnkd.in/eWKNNVKQ #ClinicalTrials #Mycology #AMR  Gurjinder Bains

We are delighted to see the growth of our LinkedIn following and extend an invitation for you to join us on our journey. Your support is integral as we confront critical global health issues such as antimicrobial resistance (AMR), and advocate for patients rare disease fields. We also continue to make positive strides in our specialised area of infectious disease. At Shionogi Europe, we do things differently. Our unique DNA combines our Japanese roots with our strong and rapidly growing European operation, allowing us to unleash the power of our scientific expertise. Healthcare systems are facing unprecedented challenges. To ensure the well-being of patients and societies, and to meet the needs of future generations, we believe in the power of open collaboration, fresh imagination, and bold action. Are you curious to learn more about how we are shaping the future of healthcare? Visit: https://lnkd.in/e4riEiuN to discover more about our mission and values. #ShionogiEurope #InfectiousDisease #RareDisease #AMR

We are determined to progress our aim of supporting people to live a healthy and prosperous life, helping to create a society where everyone can realise their goals. Hearing loss is a major global health issue, impacting around 1.5 billion people¹. Supporting people with hearing loss is a priority for us, and we’re proud of our educational project 'Communication Barrier Free', which aims to encourage effective communication between healthcare professionals and patients. We can achieve far more in partnership too, so we are delighted to be working closely with Cilcare to meet unmet medical needs in this area. #HealthcareInnovation #HearingLoss #GlobalHealth #Pharmaceuticals #Shionogi #Cilcare Reference: 1. https://lnkd.in/erV9_Gdc

📜 In April 2023, the European Commission proposed the revision of the General Pharmaceutical Legislation (#GPL). Less than a year later, the European Parliament adopted its reports on this proposal, while the Council of the European Union is currently scrutinising it. 🗣️ We reached out to EUCOPE’s Members to gather their reflections on key elements of the revision of the GPL, and how it will impact small and mid-sized companies in the #EU. 🩹On this Wednesday’s #GPLinsights, Huw Tippett, CEO of Shionogi Europe, shared his thoughts on what is needed to fight antimicrobial resistance (#AMR). He emphasised that only clear and adequate #incentives will encourage #investments to develop novel #antibiotics and protect EU citizens.